Lingyin assists the firm in biotechnology patent prosecution. She has extensive knowledge in the areas of immunology, miRNA biology, pulmonary diseases and translational research.
Prior to joining Wolf Greenfield, Lingyin was a project scientist Cedars-Sinai Medical Center. She conducted research on pulmonary fibrosis and lung injury. Lingyin also interned in the tech transfer office at Cedars-Sinai, where she evaluated patentability and marketability of disclosed therapeutic and medical device inventions and assisted external legal counsel in drafting patent applications and office action responses.
Lingyin received her PhD from Stony Brook University. Her research focused on DBP-Actin complex serves as Danger Associated Molecular Pattern (DAMPs) to induce acute lung injury in sepsis and trauma patients.